CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −917 | $11.83 | $11K | 123,673 |
| 2025-03-05 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −1,094 | $11.83 | $13K | 197,993 |
| 2025-02-18 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,598 | $13.95 | $36K | 199,087 |
| 2025-02-18 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −2,488 | $13.95 | $35K | 124,590 |
| 2025-01-27 | Rhodes Jason P Director | Grant or award | +1,111,111 | $13.50 | $15.0M | 1,958,427 |
| 2024-12-11 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,334 | $28.12 | $66K | 201,685 |
| 2024-12-11 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,455 | $28.12 | $41K | 127,078 |
| 2024-12-09 | Kersten Dirk Director | Sale | −34,437 | $29.18 | $1.0M | 5,400,545 |
| 2024-12-06 | Kersten Dirk Director | Sale | −101,675 | $29.34 | $3.0M | 5,434,982 |
| 2024-12-05 | Kersten Dirk Director | Sale | −3,806 | $29.05 | $111K | 5,536,657 |
| 2024-12-04 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award | +37,800 | 96,200 | ||
| 2024-12-04 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award · Stock option (right to buy) | +60,300 | 60,300 | ||
| 2024-12-04 | Kersten Dirk Director | Sale | −135,039 | $29.39 | $4.0M | 5,540,463 |
| 2024-12-04 | Scalzo Richard William SVP, Head of Finance & Admin. | Grant or award | +32,700 | 128,533 | ||
| 2024-12-04 | Scalzo Richard William SVP, Head of Finance & Admin. | Grant or award · Stock option (right to buy) | +52,300 | 52,300 | ||
| 2024-12-04 | Kerr Douglas Chief Medical Officer | Grant or award | +48,000 | 95,500 | ||
| 2024-12-04 | Kerr Douglas Chief Medical Officer | Grant or award · Stock option (right to buy) | +76,600 | 76,600 | ||
| 2024-12-04 | Cox John CEO & President | Grant or award | +145,300 | 150,300 | ||
| 2024-12-04 | Cox John CEO & President | Grant or award · Stock option (right to buy) | +232,100 | 232,100 | ||
| 2024-12-04 | Beskrovnaya Oxana Chief Scientific Officer | Grant or award | +39,100 | 176,619 |
Page 10 of 29 · 561 trades